3-乙基金刚烷羧酸 | 37845-05-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-乙基金刚烷羧酸
• 中文别名: 3-乙基-1-金刚烷甲酸
• 英文名称: 3-ethyladamantane-1-carboxylic acid
• CAS: 37845-05-9
• 化学式: C₁₃H₂₀O₂
• mdl: MFCD00218938
• 分子量: 208.301
• InChiKey: ZJBLNYRNJSFPQO-UHFFFAOYSA-N

物化性质

• 熔点：
  94-96
• 沸点：
  327.8±10.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.923
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2916209090
• 储存条件：
  室温

SDS

Name:	3-Ethyladamantane-1-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	37845-05-9

Section 1 - Chemical Product MSDS Name:3-Ethyladamantane-1-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37845-05-9	3-Ethyladamantane-1-carboxylic acid	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37845-05-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 94 - 96 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H20O2
Molecular Weight: 208

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37845-05-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Ethyladamantane-1-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 37845-05-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37845-05-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37845-05-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-乙基金刚烷羧酸 在 4-二甲氨基吡啶 、 硫酸 、 硝酸 、 氯甲酸乙酯 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二乙二醇 为溶剂， 反应 26.0h， 生成 tert-butyl N-[3-ethyl-5-(hydroxymethyl)-1-adamantyl]carbamate
  参考文献：
  名称：

  Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases

  摘要：

  一系列甲基苯胺硝酸盐衍生物被设计和合成，作为具有神经保护和血管舒张活性的双重功能化合物，用于神经退行性疾病。

  DOI：

  10.1039/c6md00509h
• 作为产物：
  描述：

  马杜拉霉素 在 硫酸 、 水 、 sodium oxalate 作用下， 反应 5.5h， 生成 3-乙基金刚烷羧酸
  参考文献：
  名称：

  Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases

  摘要：

  一系列甲基苯胺硝酸盐衍生物被设计和合成，作为具有神经保护和血管舒张活性的双重功能化合物，用于神经退行性疾病。

  DOI：

  10.1039/c6md00509h

文献信息

• One-pot synthesis of cage alcohols
  作者：Yu. N. Klimochkin、A. V. Yudashkin、E. O. Zhilkina、E. A. Ivleva、I. K. Moiseev、Ya. F. Oshis

  DOI：10.1134/s1070428017070028

  日期：2017.7

  An efficient one-pot procedure has been developed for the synthesis of cage alcohols with hydroxy groups in the bridgehead positions. The procedure includes initial nitroxylation with nitric acid or a mixture of nitric acid with acetic acid and subsequent hydrolysis in the presence of urea.

  已经开发出一种有效的一锅法程序，用于合成在桥头位置具有羟基的笼型醇。该程序包括先用硝酸或硝酸与乙酸的混合物进行硝化，然后在尿素存在下进行水解。
• PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST
  申请人：Komiyama Masato

  公开号：US20110313169A1

  公开（公告）日：2011-12-22

  A process for efficiently producing, through few steps either a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or an intermediate therefore. The process is a novel coupling process which comprises subjecting a compound represented by formula (1) to coupling reaction with a compound represented by formula (2) in the presence of a transition metal compound to thereby obtain a compound represented by formula (3).

  一种高效生产黄嘌呤氧化酶抑制剂或其中间体的方法，该抑制剂是治疗高尿酸血症的药物。该方法是一种新型偶联过程，包括将式（1）表示的化合物与式（2）表示的化合物在过渡金属化合物存在下进行偶联反应，从而获得式（3）表示的化合物。
• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• AMANTADINE NITRATE COMPOUND HAVING A NEUROPROTECTIVE EFFECT AND PREPARATION AND MEDICAL USE THEREOF
  申请人：Guangzhou Magpie Pharmaceuticals Co., Ltd.

  公开号：EP3150574A1

  公开（公告）日：2017-04-05

  The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

  本发明涉及具有神经保护作用的金刚烷胺硝酸盐化合物，以及其制备方法和医用。这些化合物具有一般式（I）的结构。这些化合物具有多功能机制，包括抑制NMDA受体、释放NO、抑制钙离子通道进入以及对细胞特别是神经细胞具有保护作用。这些化合物可用于制备具有细胞保护作用的药物，用于预防或治疗与NMDA受体和细胞内钙离子升高相关的疾病，包括与神经退行性疾病相关的疾病，如阿尔茨海默病、帕金森病、脑瘫和青光眼，以及与心脑血管系统相关的疾病，如与脑动脉硬化相结合的帕金森综合征，以及由流感病毒引起的呼吸道感染。
• 一种金刚烷胺类硝酸酯衍生物的制备工艺
  申请人：青岛海蓝医药有限公司

  公开号：CN109206317B

  公开（公告）日：2021-07-09

  本发明公开了一种金刚烷胺类硝酸酯衍生物的制备工艺，其包括以取代或者未取代的金刚烷为原料，通过以下几步反应制备金刚烷胺类硝酸酯衍生物：(1)金刚烷醇的合成；(2)金刚烷醇的羧化；(3)金刚烷酸的酰胺化；(4)还原；(5)酰胺基金刚烷醇的水解与氨基的Boc保护；(6)Boc保护金刚烷胺醇的析晶；(7)Boc保护金刚烷胺醇的硝酸酯化；(8)硝酸酯化产物的精制；(9)氨基去保护与成盐；(10)金刚烷胺硝酸酯的精制。所述金刚烷胺类硝酸酯衍生物为：其中，R1，R2相同或不相同，分别为氢，直链或支链烷基，取代或未取代的芳基，芳杂基。本发明提供了一种高效、经济、绿色、安全、可靠并且适于工业化生产的金刚烷胺硝酸酯衍生物的制备工艺。